Compare KIDS & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | IVVD |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 437.1M |
| IPO Year | 2016 | 2021 |
| Metric | KIDS | IVVD |
|---|---|---|
| Price | $16.43 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $24.67 | $8.75 |
| AVG Volume (30 Days) | 146.6K | ★ 3.5M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | $53,426,000.00 |
| Revenue This Year | $14.07 | $147.67 |
| Revenue Next Year | $11.85 | $22.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 37.95 | ★ 110.47 |
| 52 Week Low | $14.91 | $0.46 |
| 52 Week High | $23.70 | $3.07 |
| Indicator | KIDS | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 60.99 |
| Support Level | $15.70 | $1.41 |
| Resistance Level | $19.15 | $2.00 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 79.21 | 99.21 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.